Open AccessImpact of the introduction of a 13-valent pneumococcal vaccine on pneumococcal serotypes in non-invasive isolates from 2007 to 2016 at a teaching hospital in Japan
Author(s) -
Shiori Suzuki,
Ryuji Osato,
Takeaki Wajima,
Taisuke Hasebe,
Haruna Ishikawa,
Hikari Mitsumori,
Hidemasa Nakaminami,
Norihisa Noguchi
Publication year - 2019
Publication title -
journal of medical microbiology/journal of medical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.91
H-Index - 117
eISSN - 1473-5644
pISSN - 0022-2615
DOI - 10.1099/jmm.0.000992
Subject(s) - serotype , streptococcus pneumoniae , pneumococcal conjugate vaccine , penicillin , multilocus sequence typing , microbiology and biotechnology , pneumococcal infections , medicine , antibiotic resistance , virology , vaccination , typing , antibiotics , biology , genotype , gene , biochemistry
To prevent severe invasive pneumococcal infection, pneumococcal conjugate vaccines (PCVs) were introduced in Japan in 2010, and in 2013 a pneumococcal 13-valent conjugate vaccine (PCV13) was included in the routine vaccination schedule for infants. In this study, we analysed the antimicrobial susceptibilities and capsular types of pneumococci isolated from non-invasive patient sites from 2007 to 2016 to assess the impact of the introduction of PCV13.